Immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemiaJ84.0

Last updated on: 15.07.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Immunodeficiency-100 and with pulmonary alveolar proteinosis and hypogammaglobulinemia (IMD100) is caused by a heterozygous mutation in the OAS1 gene (164350) on chromosome 12q24.

EtiopathogenesisThis section has been translated automatically.

Pathogenetically, disease symptoms are related to abnormal function of alveolar macrophages leading to decreased degradation of surfactant (Cho et al. 2018). Magg et al. (2021) noted that the disease results from a gain-of-function effect that particularly affects B cells and monocytes.

The development of the disease appears to be influenced or triggered by viral infection and is manifested by progressive respiratory failure, confluent consolidations in lung imaging, and diffuse accumulations of periodic acid-Schiff (PAS)-positive material in alveoli associated with small and non-foamy alveolar macrophages.

Clinical featuresThis section has been translated automatically.

Immunodeficiency manifests primarily as pulmonary disease characterized by the onset of respiratory insufficiency due to pulmonary alveolar proteinosis (see Pulmonary Alveolar Proteinosis below) in the first months of life. Affected individuals may have normal respiratory function at birth.

In addition to progressive respiratory failure, patients also present with hypogammaglobulinemia, leukocytosis, and splenomegaly.

TherapyThis section has been translated automatically.

Hematopoietic stem cell transplantation (HSCT) can lead to a cure.

Progression/forecastThis section has been translated automatically.

Many patients die in infancy or early childhood from respiratory failure

LiteratureThis section has been translated automatically.

  1. Cho K et al. (2006) Successful treatment of congenital pulmonary alveolar proteinosis with intravenous immunoglobulin G administration. Respirology 11: 74-77.
  2. Cho K et al (2018) Heterozygous mutations in OAS1 cause infantile-onset pulmonary alveolar proteinosis with hypogammaglobulinemia. Am J Hum Genet 102: 480-486.
  3. Magg T et al (2021) Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency. Sci Imm 6: eabf9564.
  4. Tanaka-Kubota M et al (2018) Hematopoietic stem cell transplantation for pulmonary alveolar proteinosis associated with primary immunodeficiency disease. Int J Hemat 107: 610-614.

Last updated on: 15.07.2022